bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C041: A systematic review of cardiovascular health among cancer survivors
Authors: Miles Miriam A. , Anderson-Tolbert Le’Andrea , Ninson Abigail A. , Means Cha-Breia , Smith Tuchondriana , Coleman Reagan , Rogers Laura , Joseph Joshua , Nolan Timiya S. 
Published: September 2024

Abstract
Purpose: The most common non-cancer cause of death among cancer survivors is cardiovascular disease. Health behaviors (e.g., diet, physical activity, sleep, smoking) and health factors (e.g., blood pressure, hemoglobin A1C, cholesterol) associated with cancer mortality are also associated with cardiovascular mortality. The American Heart Association has termed these behaviors and factors “cardiovascular health” (CVH) or “Life’s Essential 8,” providing a metric to determine poor, intermediate, and high (ideal) CVH. Less than ideal CVH is associated with higher cancer mortality; however, little is known about the CVH of cancer survivors. The purpose of this systematic review is to examine the extant literature on CVH among cancer survivors. MethodsIn accordance with PRISMA guidelines, we are systematically examining cardiovascular health among cancer survivors (including patients) within PubMed, Scopus, CINAHL, and Embase databases without date limitations. Two reviewers are accessing articles at each level of review to determine concordance with inclusion criteria, coming to consensus via a shared discussion. Data from studies that meet inclusion criteria will be abstracted, assessed for risk of bias. and synthesized to understand themes of CVH among cancer survivors. Results To date, we have retrieved 1,990 studies from the named databases. Preliminary review of the title and abstracts suggests that CVH as a metric may be seldom used within extant literature. This review is ongoing. Conclusion: Given the co-morbid and iatrogenic nature of cardiovascular disease among cancer survivors, it is important to understand metrics that can be applied to both identify cancer survivors with increased risk of poor outcomes and educate/empower cancer survivors to make modifiable changes to reduce their risk. This review will provide much needed evidence to support future research, practice changes, and policy implications to support the long-term health of cancer survivors.
Citation Format: Miriam A. Miles, Le’Andrea Anderson-Tolbert, Abigail A. Ninson, Cha-Breia Means, Tuchondriana Smith, Reagan Coleman, Laura Rogers, Joshua Joseph, Timiya S. Nolan. A systematic review of cardiovascular health among cancer survivors [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C041.
Abstract C056: Improving Adherence to Cancer Care in Underserved Patients with Central Nervous System Tumors through the Integrated Cancer Care Access Network (ICCAN)
Authors: Elshiekh Cleopatra , Phillips Ashley , Rodriguez Ashley , Narang Bharat , Gany Francesca , Budhu Joshua 
Published: September 2024

Abstract
This pilot study investigates the impact of the Integrated Cancer Care Access Network (ICCAN) on treatment adherence for patients with central nervous system (CNS) tumors. Patients with CNS tumors often face significant financial toxicity due to a lack of ability to work, physical disabilities due to their disease, and cognitive changes due to treatment and disease. Patients were enrolled in the ICCAN intervention, a longstanding multidisciplinary patient navigation and socioeconomic resources facilitation program, where an initial essential needs survey was administered. The survey consisted of questions regarding food security, housing circumstances, monthly individual and household income, and transportation barriers that patients were facing. If patients could not complete the survey independently due to their disease, a caregiver helped answer the survey questions. The clinical research coordinator helped procure appropriate resources based on the needs expressed. Patient navigation services were also provided to facilitate patient engagement and adherence to treatment and appointments. Patients were provided access to the Memorial Sloan Kettering food pantry, gift card services, assistance applying for grants, and transportation assistance. Patients were followed at 2 months, 4 months, 6 months, and 12 months post the initial essential needs survey. Overall, the largest needs for the CNS tumor patients enrolled in ICCAN were housing, income due to lack of ability to work, food insecurity, and transportation barriers for appointments. Many patients expressed gratitude for the services provided and consistently followed up with the clinical research coordinator regarding any apparent new needs. There is a lack of research on the financial toxicity of patients with CNS tumors, and this pilot program provided proof of concept that patients with CNS tumors can be successfully enrolled in a patient navigation and resources intervention. Based on this data, we will expand this intervention into a randomized clinical trial.
Citation Format: Cleopatra Elshiekh, Ashley Phillips, Ashley Rodriguez, Bharat Narang, Francesca Gany, Joshua Budhu. Improving Adherence to Cancer Care in Underserved Patients with Central Nervous System Tumors through the Integrated Cancer Care Access Network (ICCAN) [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C056.
Abstract C072: Evaluating the use of vincristine as a substitute for vinblastine in Hodgkin lymphoma treatment
Authors: Sarhan Zaid , Atmeh Mousa , Al-Saudi Mohammad , AlFattah AlNsour Abed , Alghafri Osama , AlDin Sarhan Dia’a , Al-Dalaeen Raneem 
Published: September 2024

Abstract
Introduction: Classical Hodgkin lymphoma (HL) is a type of cancer originating from B lymphocytes, characterized by a high annual incidence globally. While the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) is the standard treatment, this study explores substituting Vinblastine with Vincristine (ABOD regimen) to potentially enhance efficacy and treatment outcomes. Purpose: The primary aim was to evaluate the efficacy of the ABOD regimen compared to the ABVD regimen in treating classical Hodgkin lymphoma. The study also aimed to identify factors influencing treatment response, relapse risk, and the indication for alternative treatments such as escalation therapy, salvage therapy, immunotherapy, and transplantation. Method: This retrospective study reviewed 83 patients diagnosed with classical HL and treated at the Military Cancer Center in Jordan from January 1, 2017, to February 1, 2023. Data on demographics, disease characteristics, treatment regimens, and outcomes were collected and analyzed using logistic regression and Chi-square tests to evaluate associations between variables and treatment outcomes. Results: The study included 83 patients, with a mean age of 35.67 years, and a predominance of females (60.24%). The most common subtype was nodular sclerosis (84.34%), with stage 4 disease being the most prevalent (45.12%). Treatment response after the second cycle of ABOD was significantly better in older patients. There was no significant association between bulky disease and treatment response or relapse risk. Younger patients required dose escalation more frequently, suggesting the ABOD regimen might be more suitable for older patients. Gender, histological subtype, and disease stage were not significantly associated with treatment response or relapse risk. Conclusion: The ABOD regimen, using vincristine instead of vinblastine, presents a viable alternative to the ABVD regimen for classical Hodgkin lymphoma treatment, particularly benefiting older patients due to favorable response rates and manageable toxicity. The findings highlight the need for further research to optimize treatment strategies for different patient subgroups and confirm the benefits of the ABOD regimen.
Citation Format: Zaid Sarhan, Mousa Atmeh, Mohammad Al-Saudi, Abed AlFattah AlNsour, Osama Alghafri, Dia’a AlDin Sarhan, Raneem Al-Dalaeen. Evaluating the use of vincristine as a substitute for vinblastine in Hodgkin lymphoma treatment [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C072.
Abstract C076: Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities
Authors: Rangel Valeria , Quintero-Rivera Fabiola , Tanjasiri Sora , Masri Selma , Fleischman Angela , Pannunzio Nicholas R. 
Published: September 2024

Abstract
Activation-induced cytidine deaminase (AID) is a B cell-specific mutator required for antibody diversification. However, it is also implicated in the etiology of several B cell malignancies. Evaluating the AID-induced mutation load in patients at-risk for certain blood cancers is critical in assessing disease severity and treatment options. We have developed a digital PCR (dPCR) assay that allows us to quantify mutations resulting from AID modification or DNA double-strand break (DSB) formation and repair at sites known to be prone to DSBs. Implementation of this new assay showed that increased AID levels in immature B cells increased genome instability at loci linked to chromosomal translocation formation. This included the CRLF2 locus that is often involved in translocations associated with a subtype of acute lymphoblastic leukemia (ALL) that disproportionately affects Hispanics, particularly those with Latin American ancestry. Using dPCR, we characterized the CRLF2 locus in B cell-derived genomic DNA from both Hispanic ALL patients and healthy Hispanic donors and found increased mutations in both, suggesting that vulnerability to DNA damage at CRLF2 may be driving this health disparity. Our ability to detect and quantify these mutations will potentiate future risk identification, early detection of cancers, and reduction of associated cancer health disparities.
Citation Format: Valeria Rangel, Fabiola Quintero-Rivera, Sora Tanjasiri, Selma Masri, Angela Fleischman, Nicholas R. Pannunzio. Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C076.
Abstract C080: Glioma cell-mediated hyper-thrombotic tumor microenvironment drives glioblastoma growth
Authors: Bukenya George , Sloan Anthony , Horbinski Craig , Gupta Anirban Sen , Cameron Scott , Lathia Justin 
Published: September 2024

Abstract
Cancer-related thrombosis is the second leading cause of death for cancer patients, including those with glioblastoma (GBM), the most common primary malignant brain tumor. Patients with GBM have a 30% risk of venous thromboembolism (VTE). High platelet counts, and increased platelet reactivity are associated with poor clinical outcomes in many cancers. While platelets are known to promote progression of tumors, the mechanisms by which these changes in platelet reactivity act as a driver for GBM progression is unknown. Our previous work demonstrated that a subpopulation of glioma cells activates platelets to promote GBM cell growth by intrinsically producing thrombin via a cell intrinsic functional coagulation cascade. These findings provided evidence that glioma cells can readily execute a highly liver-specific gene expression program that contributes to a hyper-thrombotic state in the GBM tumor microenvironment (TME). We now demonstrate thrombin and platelet expression in GBM patient specimen creates a hyper-thrombotic GBM tumor-microenvironment and that GBM patient platelets have increased reactivity compared to healthy patients. Further, genetic targeting of the intrinsic coagulation cascade, via knockdown of coagulation factor 11 (F11) and coagulation factor 12 (F12), reduces glioma cell growth and tumor formation while also decreasing the ability for glioma cells to activate platelets, subsequently decreasing the hyper-thrombotic state seen in the GBM tumor microenvironment. Our observations suggest that glioma cells execute a cell intrinsic coagulation mechanism to contribute to the hyper-thrombotic tumor-microenvironment seen in GBM and may shed light onto mechanisms of cancer associated thrombosis in not only GBM, but also other malignancies.
Citation Format: George Bukenya, Anthony Sloan, Craig Horbinski, Anirban Sen Gupta, Scott Cameron, Justin Lathia. Glioma cell-mediated hyper-thrombotic tumor microenvironment drives glioblastoma growth [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C080.
Abstract C085: Somatic mutational profiles of breast tumors from Hispanic/Latino women
Authors: Ding Yuan Chun , Tao Shu , Mao Allen , Ziv Elad , Neuhausen Susan L. 
Published: September 2024

Abstract
Background: Breast cancer is the leading cause of cancer mortality among Hispanic/Latina (H/L) women. Precision medicine holds promise for more effective treatments by targeting therapies based on somatic mutations, copy number changes, mutational signatures, and/or germline risk variants. However, there is a paucity of genomics data for H/L women with breast cancer leading to a disparity in the application of precision medicine. We have previously characterized mutational profiles of 146 breast tumors from 140 H/L women. Here, we analyze data from whole exome tumor/normal sequencing and tumor RNA sequencing from 430 self-reported H/L breast cancer cases and compare their profiles to 385 tumors from self-reported White breast cancer cases. Methods: All participants were treated at City of Hope and all sequencing data were generated using Ashion GEM ExTra (Exact Sciences). Tumor/germline sequence data were aligned to the human genome (Build37) and variants were called using the FreeBayes workflow. To determine significantly mutated genes, we used MutSigCV and dNdS. We used Fisher’s exact test to determine if the frequency of somatic mutations was significantly different among H/L women and White women and corrected for multiple hypothesis testing using Benjamini-Hochberg false discovery rate (FDR). Results: Seventeen genes and 19 genes had q-values &lt; 0.05 in H/L and White samples, respectively. Of those, AKT1, CBFB, FOXA1, MAP2K4, MAP3K1, MLL3, PIK3CA, PTEN, RB1, RUNX1, TBX3, TP53, and ZFPM1 were significantly mutated in both. CTCF and HS6ST1 were significantly mutated only in tumors from H/L. ARID1A, CDKN1B, NCOR1, and PRRT2 were significantly mutated only in tumors from White women. There was a significantly higher frequency of TP53 mutations (FDR q-value = 0.007) and CTCF mutations (FDR q-value = 0.057) in tumors from H/L compared to tumors from Whites. Conclusions: We found TP53 and CTCF to be more commonly mutated in tumors from H/L women. CTCF mutations are seen in other tumor types, but our study is the first to demonstrate that this gene is significantly mutated in breast cancer in any population. Since CTCF is a broadly active transcriptional regulator, tumors with these mutations may be associated with broad dysregulation of gene expression.
Citation Format: Yuan Chun Ding, Shu Tao, Allen Mao, Elad Ziv, Susan L. Neuhausen. Somatic mutational profiles of breast tumors from Hispanic/Latino women [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C085.
Abstract C095: Molecular characterization of gastric adenocarcinoma from Latinos shows homologous recombination deficiency
Authors: Montoya Dennis J , Estrada-Florez Ana , Lott Paul , Chiu Katherine , Suarez-Olaya John , Castro Fabian , Echeverry de Polanco Magdalena , Torres Javier , Bohorquez Mabel , Carvajal-Carmona Luis 
Published: September 2024

Abstract
Latinos have a higher risk of developing gastric cancer (GC) than non-Latino Whites (NLW). Multiple studies have shown increased treatment resistance in diffuse-type cancers, which are more prevalent in Latino patients and dominated by the genomically stable (GS) genomic subtype. However, there is little genomic data from Latino gastric tumors due to the few studies targeting this minority population. Here, we attempt to rectify the disparity of genomic data by performing whole exome and/or low-coverage whole genome sequencing on tumors from 195 Latino gastric adenocarcinoma patients, from Colombia and Mexico. We also analyze 42 Latino patients from the US from a previous study. In total, we analyze tumors from 237 patients, the largest cohort of Latino gastric cancer tumors comprehensively sequenced thus far. Molecular subtyping of our cohort shows a higher proportion of tumors with a genomically stable (GS) subtype, 59%, and less with chromosomal instability (CIN), 24%, than reported in non-Latino patients from the Cancer Genome Atlas (20% and 50% respectively). Our earlier study of germline variants from Latinos, indicated a potential enrichment of variant related to homologous recombination deficiency (HRD), an important DNA repair mechanism. Focusing on this pathway, we performed HRD scoring and show that CIN tumors had the highest HRD score compared to all other subtypes. An alternative method analyzing somatic mutational patterns identified an indel mutational signature (ID6), also related to HRD, was enriched in GS tumors. Overall, these data provide a broader picture of the genomic landscape of Hispanic tumors, highlighting HRD targeting drugs as a potential treatment for both GS diffuse-types cancers particularly seen in Latinos and CIN tumors found more generally in gastric cancer.
Citation Format: Dennis J Montoya, Ana Estrada-Florez, Paul Lott, Katherine Chiu, John Suarez-Olaya, Fabian Castro, Magdalena Echeverry de Polanco, Javier Torres, Mabel Bohorquez, Luis Carvajal-Carmona. Molecular characterization of gastric adenocarcinoma from Latinos shows homologous recombination deficiency [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C095.
Abstract C105: Novel cancer-specific hypoxia signature predicts poor prognosis and highlights racial disparities in breast cancer
Authors: Schechter Kent , Nguyen Long C. , Yerradoddi Geetha P. , Bassiouni Rania , Carpten John D. , Rosner Marsha R. 
Published: September 2024

Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. TNBC displays exceptional transcriptional heterogeneity, both between patients and intratumorally, and disproportionately affects underserved women. Hypoxia, a state of low oxygen levels, is often present in the solid tumor microenvironment. In TNBC, hypoxia is a key driver of aggressiveness and therapeutic resistance. Past bulk RNA sequencing (RNAseq) studies in cancer research have lacked spatial resolution, failing to uncover precise transcriptional differences within tumor regions. This spatial limitation has been especially problematic for studying transcriptional heterogeneity of the cellular hypoxia response within tumors. By integrating single-cell RNA sequencing and spatial transcriptomic analyses in a TNBC xenograft tumor model, our research has uncovered a novel hypoxia gene signature, specific to cancer cells. Elevated expression of this hypoxia signature predicts poorer prognosis in breast cancer patients, especially within TNBC patients and those of African ancestry. This suggests that hypoxia may play a role in the racial disparities observed in TNBC prognosis, potentially informing treatment strategies. This workflow introduces a novel framework for translating general spatial transcriptomics data into clinically relevant and accurate gene signatures.
Citation Format: Kent Schechter, Long C. Nguyen, Geetha P. Yerradoddi, Rania Bassiouni, John D. Carpten, Marsha R. Rosner. Novel cancer-specific hypoxia signature predicts poor prognosis and highlights racial disparities in breast cancer [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C105.
Abstract C107: Differential gene expression analysis comparing Black and White patients with HPV-positive oropharyngeal squamous cell carcinoma reveals suppressed immune response and higher rates P16/HPV DNA discordance in Black patients
Authors: Watts Tammara L. , Gonzalez Katerine , Shen Xiangfeng , Rogers Layne , Osazuwa-Peters Nosa , Jefferson Gina D. , Clement Cecilia G. , Range Danielle , Kahmke Russel R. , Lee Walter T. , Rocke Daniel J. , Cannon Trinitia Y. , Mowery Yvonne , Owzar Kouros 
Published: September 2024

Abstract
This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR004) of the Conference Program/Proceedings. Cell, Molecular, and Tumor Biology: Cell Growth Signaling Pathways
Citation Format: Tammara L. Watts, Katerine Gonzalez, Xiangfeng Shen, Layne Rogers, Nosa Osazuwa-Peters, Gina D. Jefferson, Cecilia G. Clement, Danielle Range, Russel R. Kahmke, Walter T. Lee, Daniel J. Rocke, Trinitia Y. Cannon, Yvonne Mowery, Kouros Owzar. Differential gene expression analysis comparing Black and White patients with HPV-positive oropharyngeal squamous cell carcinoma reveals suppressed immune response and higher rates P16/HPV DNA discordance in Black patients [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C107.